The estimated Net Worth of Dimitri E. Grigoriadis is at least $36.5 Milion dollars as of 7 October 2021. Dimitri Grigoriadis owns over 8,000 units of Neurocrine Biosciences stock worth over $9,993,701 and over the last 17 years he sold NBIX stock worth over $23,213,441. In addition, he makes $3,325,880 as Chief Research Officer at Neurocrine Biosciences.
Dimitri has made over 58 trades of the Neurocrine Biosciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 8,000 units of NBIX stock worth $838,480 on 7 October 2021.
The largest trade he's ever made was exercising 86,963 units of Neurocrine Biosciences stock on 13 June 2018 worth over $1,003,553. On average, Dimitri trades about 11,199 units every 40 days since 2008. As of 7 October 2021 he still owns at least 82,273 units of Neurocrine Biosciences stock.
You can see the complete history of Dimitri Grigoriadis stock trades at the bottom of the page.
Dr. Dimitri E. Grigoriadis Ph.D. serves as Chief Research Officer of the Company. Dr. Grigoriadis was appointed Chief Research Officer in 2013. Dr. Grigoriadis oversees all research functions, including drug discovery, biology and chemistry, and has led such functions since 2006. Dr. Grigoriadis joined Neurocrine Biosciences in 1993, established the pharmacology and drug screening groups and was most recently a Neurocrine Biosciences Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine Biosciences, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B.Sc. from the University of Guelph in Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990.
As the Chief Research Officer of Neurocrine Biosciences, the total compensation of Dimitri Grigoriadis at Neurocrine Biosciences is $3,325,880. There are 6 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
Dimitri Grigoriadis is 62, he's been the Chief Research Officer of Neurocrine Biosciences since 2013. There are 6 older and 17 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
Dimitri's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 21 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: